BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 20224542)

  • 1. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(21):394-5. PubMed ID: 22647745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(40):816-9. PubMed ID: 23051612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.
    Paradiso PR
    Clin Infect Dis; 2011 May; 52(10):1241-7. PubMed ID: 21507921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated.
    ;
    MMWR Morb Mortal Wkly Rep; 2008 Apr; 57(13):343-4. PubMed ID: 18385642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.
    Yeh SH; Gurtman A; Hurley DC; Block SL; Schwartz RH; Patterson S; Jansen KU; Love J; Gruber WC; Emini EA; Scott DA;
    Pediatrics; 2010 Sep; 126(3):e493-505. PubMed ID: 20732948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jun; 62(25):521-4. PubMed ID: 23803961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Tomczyk S; Bennett NM; Stoecker C; Gierke R; Moore MR; Whitney CG; Hadler S; Pilishvili T;
    MMWR Morb Mortal Wkly Rep; 2014 Sep; 63(37):822-5. PubMed ID: 25233284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Kobayashi M; Bennett NM; Gierke R; Almendares O; Moore MR; Whitney CG; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2015 Sep; 64(34):944-7. PubMed ID: 26334788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    ;
    MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.
    Rubin JL; McGarry LJ; Strutton DR; Klugman KP; Pelton SI; Gilmore KE; Weinstein MC
    Vaccine; 2010 Nov; 28(48):7634-43. PubMed ID: 20883739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.